$34.00−1.44 (−4.06%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Omnicell (OMCL) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~1.1%/yr (FY21→FY25), net margin 0.2%, and free cash flow (~$86.9M) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▲6.5%
1,184.8
FY21→FY25CAGR +1.1%/yr
Net income ($M)▼83.6%
2.1
one-off year: see footnoteCAGR −59.7%/yr
Free cash flow ($M)▼42.6%
86.9
FY21→FY25CAGR −19.1%/yr
Diluted EPS▼85.2%
0.04
buyback-liftedCAGR −60.4%/yr
What the receipts whisper · what a headline number hides
Share count
−3.3%
47.9mn → 46.4mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$40.4M
steady at 3.4% of revenue (+10.8% YoY).
Returns vs FCF
89%
$77.6M returned vs $86.9M of FCF in FY25. Buybacks covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
0¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 49.0% → 42.5%. Net margin 0.2% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 1,243,923.0 | 1,184,845.0 | 1,112,238.0 | 1,147,112.0 | 1,295,947.0 | 1,132,018.0 | ▲6.5% | +1.1% |
Cost of revenue | 682,474.0 | 681,403.0 | 641,235.0 | 650,272.0 | 706,960.0 | 577,365.0 | ▲6.3% | +4.2% |
Gross profit | 561,449.0 | 503,442.0 | 471,003.0 | 496,840.0 | 588,987.0 | 554,653.0 | ▲6.9% | −2.4% |
Research & development | 86,722.0 | 88,672.0 | 90,412.0 | 97,115.0 | 104,969.0 | 75,716.0 | ▼1.9% | +4.0% |
Selling, general & admin | 410,076.0 | 409,610.0 | 380,254.0 | 434,593.0 | 486,341.0 | 389,430.0 | ▲7.7% | +1.3% |
Total operating expenses | 496,798.0 | 498,282.0 | 470,666.0 | 531,708.0 | 591,310.0 | 465,146.0 | ▲5.9% | +1.7% |
Operating incomefeeds ROC rank | 64,651.0 | 5,160.0 | 337.0 | −34,868.0 | −2,323.0 | 89,507.0 | ▲1431.2% | −51.0% |
Other income, net | 2,590.0 | 6,165.0 | 25,256.0 | 14,760.0 | −130.0 | −23,500.0 | — | — |
Pretax income | 67,241.0 | 11,325.0 | 25,593.0 | −20,108.0 | −2,453.0 | 66,007.0 | ▼55.7% | −35.6% |
Income tax | 22,576.0 | 9,273.0 | 13,062.0 | 263.0 | −8,101.0 | −11,842.0 | ▼29.0% | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 44,665.0 | 2,052.0 | 12,531.0 | −20,371.0 | 5,648.0 | 77,849.0 | ▼83.6% | −59.7% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 0.96 | 0.04 | 0.27 | −0.45 | 0.12 | 1.62 | ▼85.2% | −60.4% |
Diluted shares (mn) | 46.47 | 46.36 | 46.26 | 45.21 | 45.89 | 47.94 | ▲0.2% | −0.8% |
| Margins | ||||||||
Gross margin25th pct in Healthcare | 45.1% | 42.5% | 42.3% | 43.3% | 45.4% | 49.0% | ▲0.1pp | −6.5pp |
Operating margin | 5.2% | 0.4% | 0.0% | −3.0% | −0.2% | 7.9% | ▲0.4pp | −7.5pp |
Net margin52nd pct in Healthcare | 3.6% | 0.2% | 1.1% | −1.8% | 0.4% | 6.9% | ▼1.0pp | −6.7pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was −18% vs a 51% norm for this window, likely a one-time item; see the filing.FY22 effective tax rate was 330% vs a 51% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Omnicell's revenue last fiscal year?
Omnicell reported revenue of $1,184.8M in fiscal 2025, up 6.5% from fiscal 2024.
What was Omnicell's net income?
Omnicell reported net income of $2.1M in fiscal 2025, a net margin of 0.2%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

